Nucleoside analogues and nucleobases in cancer treatment.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  The Lancet Oncology

• Publication date

  2002-07-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/S1470-2045(02)00788-XPMID 12142171
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• S-acyl-2-thioethyl (SATE) pronucleotides are potent inhibitors of HIV-1 replication in T-lymphoid cells cross-resistant to deoxycytidine and thymidine analogs.

  2002cited by this paper
• Gemcitabine and carboplatin for patients with advanced non-small cell lung cancer.

  2001cited by this paper
• Innovative treatments for non-small cell lung cancer.

  2001cited by this paper
• Innovative treatments for

  2001cited by this paper
• Nucleoside analogues: mechanisms of drug resistance and reversal strategies

  2001cited by this paper
• Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia.

  2001cited by this paper
• Gemcitabine/carboplatin in advanced urothelial cancer.

  2001cited by this paper
• The expanding role of mitochondria in apoptosis.

  2001cited by this paper
• Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

  2001cited by this paper
• Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.

  2001cited by this paper
• UFT in the treatment of colorectal and breast cancer.

  2001cited by this paper
• Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.

  2001cited by this paper
• Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.

  2001cited by this paper
• Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis.

  2001cited by this paper
• Remission induction therapy: the more intensive the better?

  2001cited by this paper
• Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation.

  2001cited by this paper
• Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine

  2000cited by this paper
• Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.

  2000cited by this paper
• A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.

  2000cited by this paper
• Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.

  2000cited by this paper
• Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.

  2000cited by this paper
• Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.

  1999cited by this paper
• Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone.

  1999cited by this paper
• Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

  1999cited by this paper
• Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine

  1998cited by this paper
• Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.

  1998cited by this paper
• Potentiation of lonidamine and diazepam, two agents acting on mitochondria, in human glioblastoma treatment.

  1998cited by this paper
• Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.

  1998cited by this paper
• Phase I and pharmacologic study of oral (E)-2′-deoxy-2′-(fluoromethylene) cytidine: on a daily × 5-day schedule

  1998cited by this paper
• Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

  1998cited by this paper
• Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.

  1998cited by this paper
• Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.

  1998cited by this paper
• Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts.

  1998cited by this paper
• Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.

  1998cited by this paper
• Nucleoside transport and its significance for anticancer drug resistance.

  1998cited by this paper
• Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.

  1998cited by this paper
• The oral fluorouracil prodrugs.

  1998cited by this paper
• Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC).

  1998cited by this paper
• Relationship Between Cladribine (CDA) Plasma, Intracellular Cda-5′-Triphosphate (CDATP) Concentration, Deoxycytidine Kinase (DCK), and Chemotherapeutic Activity in Chronic Lymphocytic Leukemia (CLL)

  1998cited by this paper
• Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer.

  1998cited by this paper
• Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL).

  1998cited by this paper
• 2-Chloro-2'-deoxyadenosine, an antileukemic drug, has an early effect on cellular mitochondrial function.

  1997cited by this paper
• Decreased vascular endothelial growth factor expression associated with tumor regression induced by (E)-2'-deoxy-2'-(fluoromethylene)cytidine (MDL 101,731).

  1997cited by this paper
• Combination therapy with gemcitabine in non-small cell lung cancer.

  1997cited by this paper
• Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein.

  1997cited by this paper
• Gemcitabine: preclinical pharmacology and mechanisms of action.

  1996cited by this paper
• Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.

  1996cited by this paper
• Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.

  1996cited by this paper
• FLAG (Fludarabine, Cytarabine, G‐CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: in vitro and in vivo effects

  1996cited by this paper
• Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.

  1995cited by this paper
• Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.

  1995cited by this paper
• Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration.

  1995cited by this paper
• Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia.

  1995cited by this paper
• Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

  1995cited by this paper
• Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.

  1995cited by this paper
• Induction of apoptosis by gemcitabine.

  1995cited by this paper
• In vitro transcription of DNA containing 2-chloro-2'-deoxyadenosine monophosphate.

  1995cited by this paper
• Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.

  1994cited by this paper
• Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

  1993cited by this paper
• Substrate specificity of mitochondrial 2'-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine.

  1993cited by this paper
• Biochemical modulation of arabinosylcytosine for therapy of leukemias.

  1993cited by this paper
• 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines.

  1993cited by this paper
• Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine.

  1992cited by this paper
• Cladribine (2-chlorodeoxyadenosine)

  1992cited by this paper
• Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study.

  1992cited by this paper
• Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.

  1992cited by this paper
• A comparison of the abilities of nitrobenzylthioinosine, dilazep, and dipyridamole to protect human hematopoietic cells from 7-deazaadenosine (tubercidin).

  1992cited by this paper
• Metabolism and action of purine nucleoside analogs.

  1991cited by this paper
• Comparative DNA strand breakage induced by FUra and FdUrd in human ileocecal adenocarcinoma (HCT-8) cells: relevance to cell growth inhibition.

  1991cited by this paper
• Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism.

  1991cited by this paper
• Cytarabine and neurologic toxicity.

  1991cited by this paper
• Metabolism and action of fludarabine phosphate.

  1990cited by this paper
• Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity.

  1990cited by this paper
• Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase.

  1988cited by this paper
• Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.

  1987cited by this paper
• Pericarditis induced by high-dose cytarabine therapy.

  1984cited by this paper
• Paradoxical behavior of 6-mercaptopurine as a cytotoxic agent: decreasing cell kill with increasing drug dose.

  1983cited by this paper
• Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells.

  1983cited by this paper
• Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.

  1983cited by this paper
• Metabolism and mechanisms of action of 9-(tetrahydro-2-furyl)-6-mercaptopurine in Chinese hamster ovary cells.

  1982cited by this paper
• Cytosine arabinoside influx and nucleoside transport sites in acute leukemia.

  1982cited by this paper
• The target cell determinants of the antitumor actions of 5-FU: does FU incorporation into RNA play a role?

  1981cited by this paper
• The target cell determinants of the antitumor actions of 5-FU: does FU incorporation into RNA play a role?

  1981cited by this paper
• Utilization of 2'-deoxy-6-thioguanosine 5'-triphosphate in DNA synthesis in vitro by DNA polymerase alpha from calf thymus.

  1979cited by this paper

• In silico investigation combining ADMET prediction, periodic DFT calculations, molecular docking, and nanocarrier-based drug delivery analysis for leukemia drugs using a B₂N nanosheet

  2026cites this paper
• Harnessing the Excited States of 5-(5-Phenylthiophen-2-yl)-6-Azauridine as a Three-Pronged Agent for Skin Cancer Therapy: Photodynamic Action, Cell Imaging, and Cancer Cell Inhibition.

  2025cites this paper
• Synthesis, Characterization, and DFT Calculations of a Copper(II) Complex with Lamivudine

  2025cites this paper
• Exploring the Interactions of N7-Platinated Guanosines with the hCNT3 Transporter: A Molecular Dynamics Study

  2025cites this paper
• One pot access to 2-iodo-2-deoxy nucleosides directly from glycals and unprotected nucleobases and their biological evaluation on the Japanese Encephalitis Virus

  2025cites this paper
• 5'-S-(3-aminophenyl)-5'-thioadenosine, a novel chemoprotective agent for reducing toxic side effects of fluorouracil in treatment of MTAP-deficient cancers.

  2025cites this paper
• Molecular evolution of nucleoside deoxyribosyl transferase to enhance the activity toward 2’-fluoro-2’-deoxynucleoside

  2025cites this paper
• Targeting base excision repair in precision oncology.

  2025cites this paper
• Targeting Genome Maintenance Defects of Cancers Using Chain‐Terminating Nucleoside Analogs

  2025cites this paper
• Guanine derivatives as promising candidates for the development of purine-based antimalarial drugs

  2025influential citation
• Azvudine Suppresses Epithelial–Mesenchymal Transition in Hepatocellular Carcinoma by Targeting the Notch–HEY Signalling Pathway

  2025cites this paper
• CDADC1 is a vertebrate-specific dCTP deaminase that metabolizes gemcitabine and decitabine to prevent cellular toxicity

  2025cites this paper
• Checkpoint-Dependent Sensitivities to Nucleoside Analogues Uncover Specific Patterns of Genomic Instability

  2025cites this paper
• Developing novel Lin28 inhibitors by computer aided drug design

  2025cites this paper
• Radiosensitization of Cancer Cells by 5-Selenocyanato- and 5-Trifluoromethanesulfonyl- Derivatives of 2'-deoxyuridine.

  2025cites this paper
• 5-ethynyluridine perturbs nuclear RNA metabolism to promote the nuclear accumulation of TDP-43 and other RNA binding proteins

  2025cites this paper
• Platinum N‐Heterocyclic Carbene Complexes Based on Adenosine: Synthesis and Antiproliferative Studies

  2025cites this paper
• Design, Synthesis, and Activity Evaluation of Novel Nucleosides as ADAR1 Inhibitor for the Treatment of Prostate Cancer.

  2025cites this paper
• Exploring the drug delivery capabilities of Nb2C MXene functionalized with oxygen and fluorine: A DFT study.

  2025cites this paper
• A glimpse into the developments, potential leads and future perspectives of anticancer cobalt complexes.

  2025cites this paper
• Investigating adsorption of 5-fluorouracil and 6-mercaptopurine on icosahedral silver nanoparticles through DFT and TDDFT

  2025cites this paper
• Molecular interactions between nucleotide drug isomers and cyclodextrins: Insights from ion mobility spectrometry and computational modeling

  2025cites this paper
• Discrimination of superficial lymph nodes using ultrasonography and tissue metabolomics coupled with machine learning

  2025cites this paper
• Ribonucleotide reductase (RNR) inhibitors as target-based weapon for future cancer drug development.

  2025cites this paper
• Aligning organ-specific toxicities with formulation strategies: a rational design approach to chemotherapy optimization.

  2025cites this paper
• Preparation of nucleoside analogues: opportunities for innovation at the interface of synthetic chemistry and biocatalysis

  2025cites this paper
• From Cortisone to Enlicitide: A Journey of Synthetic Chemistry Innovations at Merck

  2025cites this paper
• Synthesis, Antiproliferative Activity, and ADME Profiling of Novel Racemic and Optically Pure Aryl-Substituted Purines and Purine Bioisosteres

  2025cites this paper
• Targeting Ovarian Cancer With Pyrimidine Nucleobase and Nucleoside Analogs: Synthesis, In Vitro Cytotoxic Activity, and Molecular Docking

  2025cites this paper
• Membrane-permeable 5-fluorodeoxyuridine triphosphate derivatives inhibit the proliferation of Plasmodium falciparum

  2025cites this paper
• Repurposing zidovudine and 5-fluoro-2′-deoxyuridine as antibiotic drugs made possible by synergy with both trimethoprim and the mitochondrial toxicity–reducing agent uridine

  2024cites this paper
• Peptide hydrogel-drug conjugates for tailored disease treatment

  2024cites this paper
• Modular Access to C2'-Aryl/Alkenyl Nucleosides with Electrochemical Stereoselective Cross-Coupling.

  2024cites this paper
• PrimPol-mediated repriming elicits gap-filling by template switching and promotes cellular tolerance to cidofovir.

  2024cites this paper
• Microbial biosynthesis of nucleos(t)ide analogs: applications, and engineering optimization

  2024cites this paper
• Toxigenic effects of sponges and benthic diatoms on marine invertebrates and their possible biotechnological applications

  2024cites this paper
• Biocatalytic synthesis of ribonucleoside analogues using nucleoside transglycosylase-2

  2024cites this paper
• MAT1-1 and MAT1-2 Ophiocordyceps xuefengensis and Comparison of Their Chemical Composition

  2024cites this paper
• Gram-scale enzymatic synthesis of 2′-deoxyribonucleoside analogues using nucleoside transglycosylase-2

  2024cites this paper
• Bacterial Purine Nucleoside Phosphorylases from Mesophilic and Thermophilic Sources: Characterization of Their Interaction with Natural Nucleosides and Modified Arabinofuranoside Analogues

  2024cites this paper
• An enantioselective and modular platform for C4ʹ-modified nucleoside analogue synthesis enabled by intramolecular trans-acetalizations

  2024cites this paper
• Synthesis and Biological Profiling of Quinolino-Fused 7-Deazapurine Nucleosides

  2024cites this paper
• 2D biphenylene-based nanostructures as prospective drug delivery carriers of carvedilol and levosim: DFT study

  2024cites this paper
• Precision medicine engaging nucleoside analogues: New advances to a conventional arsenal

  2024cites this paper
• Synthesis and Evaluation of Carmofur Analogs as Antiproliferative Agents, Inhibitors to the Main Protease (Mpro) of SARS-CoV-2, and Membrane Rupture-Inducing Agents

  2024cites this paper
• Induction of Apoptotic Signaling Pathways by 3’ methyl ATP in Different Malignant Cells: in vitro Study

  2024cites this paper
• Epigenetic regulation in ovarian cancer.

  2024cites this paper
• Molecular docking and DFT study of antiproliferative ribofuranose nucleoside derivatives targeting EGFR and VEGFR2in cancer cells

  2024cites this paper
• Epigenetic Cancer Therapy

  2024cites this paper
• Connecting dots between nucleotide biosynthesis and DNA lesion repair/bypass in cancer

  2024cites this paper
• Interaction between Molnupiravir and noble metal substrates in SERS detection: A DFT method and Raman characteristic study

  2024cites this paper
• A Revisit on FDA Approved Anticancer Drugs (1949 – 2024)

  2024cites this paper
• RNA Nanotechnology for Codelivering High-Payload Nucleoside Analogs to Cancer with a Synergetic Effect.

  2024cites this paper
• ZnO nanoflowers modified pencil graphite electrode for voltammetric DNA detection and investigation of Gemcitabine–DNA interaction

  2023cites this paper
• Incorporation of N7-Platinated Guanines into Thermus Aquaticus (Taq) DNA Polymerase: Atomistic Insights from Molecular Dynamics Simulations

  2023cites this paper
• Non‐canonical nucleosides: Biomimetic triphosphorylation, incorporation into mRNA and effects on translation and structure

  2023cites this paper
• Curing Childhood Cancer the "Natural" Way: Nature as the Source of Chemotherapy Agents.

  2023cites this paper
• Fludarabine-induced bradycardia in allogeneic hematopoietic stem cell transplantation: A retrospective study

  2023cites this paper
• Understanding and targeting resistance mechanisms in cancer

  2023cites this paper
• Antitumor Activity and Reductive Stress by Platinum(II) N-Heterocyclic Carbenes based on Guanosine.

  2023cites this paper
• Neural Stem Cells as Carriers of Nucleoside-Conjugated Nanogels: A New Approach toward Cell-Mediated Delivery

  2023cites this paper
• Advanced prodrug strategies in nucleoside analogues targeting the treatment of gastrointestinal malignancies

  2023cites this paper
• Rapid plugged flow synthesis of nucleoside analogues via Suzuki-Miyaura coupling and heck Alkenylation of 5-Iodo-2’-deoxyuridine (or cytidine)

  2023cites this paper
• Combination of Tissue Microarray Profiling and Multiplexed IHC Approaches to Investigate Transport Mechanism of Nucleoside Analog Drug Resistance.

  2023cites this paper
• Single-Stranded RNA Origami-Based Epigenetic Immunomodulation.

  2023cites this paper
• Influence of the Solvent on the Stability of Aminopurine Tautomers and Properties of the Amino Group

  2023cites this paper
• Green Light-Triggerable Chemo-Photothermal Activity of Cytarabine-Loaded Polymer Carbon Dots: Mechanism and Preliminary In Vitro Evaluation

  2023cites this paper
• New established cell lines from undifferentiated pleomorphic sarcoma for in vivo study

  2023cites this paper
• Newly synthesized 6-substituted piperazine/phenyl-9-cyclopentyl containing purine nucleobase analogs act as potent anticancer agents and induce apoptosis via inhibiting Src in hepatocellular carcinoma cells.

  2023cites this paper
• Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development

  2023cites this paper
• The anti-tumor effect of trifluridine via induction of aberrant mitosis is unaffected by mutations modulating p53 activity

  2023cites this paper
• New Flexible Analogues of 8-Aza-7-deazapurine Nucleosides as Potential Antibacterial Agents

  2023cites this paper
• A Modified Nucleoside O6-methyl-2'-deoxyguanosine-5'-Triphosphate Exhibits Anti-Glioblastoma Activity in a Caspase-Independent Manner.

  2023cites this paper
• Exploring the Inclusion Complex of an Anticancer Drug with β-Cyclodextrin for Reducing Cytotoxicity Toward the Normal Human Cell Line by an Experimental and Computational Approach

  2023cites this paper
• Nucleoside-based anticancer drugs: mechanism of action and drug resistance.

  2023cites this paper
• Pharmacological and therapeutic potentials of cordycepin in hematological malignancies.

  2023cites this paper
• Therapeutic-oligonucleotides activated by nucleases (TOUCAN): A nanocarrier system for the specific delivery of clinical nucleoside analogues.

  2023cites this paper
• Electronic spectroscopy of gemcitabine and derivatives for possible dual-action photodynamic therapy applications.

  2023cites this paper
• Platinum-Nucleos(t)ide Compounds as Possible Antimetabolites for Antitumor/Antiviral Therapy: Properties and Perspectives

  2023cites this paper
• Conventional DNA-Damaging Cancer Therapies and Emerging cGAS-STING Activation: A Review and Perspectives Regarding Immunotherapeutic Potential

  2023cites this paper
• Biocatalytic Synthesis of Antiviral Nucleosides, Cyclic Dinucleotides, and Oligonucleotide Therapies

  2022cites this paper
• An insight into embryogenesis interruption by carbon nitride dots: can they be nucleobase analogs?

  2022cites this paper
• Novel pyrazolo[3,4-d]pyrimidines as potential anticancer agents: Synthesis, VEGFR-2 inhibition, and mechanisms of action.

  2022cites this paper
• Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.

  2022cites this paper
• Application of nucleoside or nucleotide analogues in RNA dynamics and RNA‐binding protein analysis

  2022cites this paper
• Ni-catalyzed Cross-coupling of 2-Iodoglycals and 2-Iodoribals with Grignard Reagents: A Route to 2-C-Glycosides and 2-C-Nucleosides.

  2022cites this paper
• Synthesis of Sugar and Nucleoside Analogs and Evaluation of Their Anticancer and Analgesic Potentials

  2022cites this paper
• Chemical and chemoenzymatic routes to bridged homoarabinofuranosylpyrimidines: Bicyclic AZT analogues

  2022cites this paper
• Aptamers Entirely Built from Therapeutic Nucleoside Analogues for Targeted Cancer Therapy.

  2022cites this paper
• 2-Nucleobase-substituted 4,6-Diaminotriazine Analogs: Synthesis and Anti-cancer Activity in 5-Fluorouracil-Sensitive and Resistant Colorectal Cancer Cells.

  2022cites this paper
• Synthesis and in silico evaluation of novel uridyl sulfamoylbenzoate derivatives as potential anticancer agents targeting M1 subunit of human ribonucleotide reductase (hRRM1)

  2022cites this paper
• Generative AI Design and Exploration of Nucleoside Analogs

  2021cites this paper
• First evidence for N7-Platinated Guanosine derivatives cell uptake mediated by plasma membrane transport processes.

  2021cites this paper
• Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR

  2021cites this paper
• 7-Aryl-7-deazapurine 3′-deoxyribonucleoside derivative as a novel lead for Chagas’ disease therapy: in vitro and in vivo pharmacology

  2021cites this paper
• Intermolecular interactions in microhydrated ribonucleoside and deoxyribonucleoside: A computational study

  2021cites this paper
• A One-Pot Synthesis of Glycans and Nucleosides Based on ortho-(1-Phenylvinyl)benzyl Glycosides.

  2021cites this paper
• DNA Damage Radiosensitizers Geared Towards Hydrated Electrons

  2021cites this paper
• Coumarins and Gastrointestinal Cancer: A New Therapeutic Option?

  2021cites this paper
• Antitumor Mechanism of Hydroxycamptothecin via the Metabolic Perturbation of Ribonucleotide and Deoxyribonucleotide in Human Colorectal Carcinoma Cells

  2021cites this paper